CY1122600T1 - Στρωματοποιηση κινδυνου σε ασθενεις με οξεια λεμφοβλαστικη λευχαιμια εκ β προδρομων - Google Patents

Στρωματοποιηση κινδυνου σε ασθενεις με οξεια λεμφοβλαστικη λευχαιμια εκ β προδρομων

Info

Publication number
CY1122600T1
CY1122600T1 CY20191100304T CY191100304T CY1122600T1 CY 1122600 T1 CY1122600 T1 CY 1122600T1 CY 20191100304 T CY20191100304 T CY 20191100304T CY 191100304 T CY191100304 T CY 191100304T CY 1122600 T1 CY1122600 T1 CY 1122600T1
Authority
CY
Cyprus
Prior art keywords
risk stratification
subjects
lymphoblastic leukemia
acute lymphoblastic
patients
Prior art date
Application number
CY20191100304T
Other languages
English (en)
Inventor
Gerhard Zugmaier
Peter Kufer
Shilpa ALEKAR
Original Assignee
Amgen Research (Munich) Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53284315&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1122600(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Research (Munich) Gmbh filed Critical Amgen Research (Munich) Gmbh
Publication of CY1122600T1 publication Critical patent/CY1122600T1/el

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)

Abstract

Η παρούσα εφεύρεση αφορά μία μέθοδο για τη στρωματοποίηση κινδύνου στα υποκείμενα που υποφέρουν από οξεία λεμφοβλαστική λευχαιμία (ALL) εκ Β προδρόμων κυττάρων, όπου τα εν λόγω υποκείμενα προορίζονται για μία θεραπεία η οποία περιλαμβάνει χορήγηση μίας επικράτειας δέσμευσης CD3. Η στρωματοποίηση του κινδύνου βασίζεται στον ορισμό της ποσότητας βλαστοκυττάρων εντός ενός δείγματος μυελού των οστών από το εν λόγω υποκείμενο, και/ή στον ορισμό του αριθμού των βλαστοκυττάρων ανά 1 μ1 εντός ενός δείγματος ΕΝΥ από το εν λόγω υποκείμενο. Σύμφωνα προς την κατηγορία στην οποία έχουν ενταχθεί τα υποκείμενα σύμφωνα με τη στρωματοποίηση κινδύνου, τα εν λόγω υποκείμενα μπορούν να υποβληθούν σε κατάλληλη θεραπευτική αγωγή, ενώ ο κίνδυνος μίας ενδεχόμενης αρνητικής νευρολογικής αντίδρασης μπορεί να μειωθεί ή ακόμη και να αποκλεισθεί.
CY20191100304T 2014-05-30 2019-03-13 Στρωματοποιηση κινδυνου σε ασθενεις με οξεια λεμφοβλαστικη λευχαιμια εκ β προδρομων CY1122600T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462005560P 2014-05-30 2014-05-30
PCT/IB2015/053705 WO2015181683A1 (en) 2014-05-30 2015-05-20 Risk-stratification of b-precursor acute lymphoblastic leukemia patients

Publications (1)

Publication Number Publication Date
CY1122600T1 true CY1122600T1 (el) 2021-03-12

Family

ID=53284315

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100304T CY1122600T1 (el) 2014-05-30 2019-03-13 Στρωματοποιηση κινδυνου σε ασθενεις με οξεια λεμφοβλαστικη λευχαιμια εκ β προδρομων

Country Status (17)

Country Link
US (1) US11079381B2 (el)
EP (3) EP3149480B1 (el)
AU (1) AU2015265578B2 (el)
CA (1) CA2948771C (el)
CY (1) CY1122600T1 (el)
DK (2) DK3531133T3 (el)
ES (2) ES2961565T3 (el)
FI (1) FI3531133T3 (el)
HR (1) HRP20231361T1 (el)
HU (2) HUE063648T2 (el)
LT (2) LT3149480T (el)
PL (2) PL3531133T3 (el)
PT (2) PT3531133T (el)
RS (1) RS64773B1 (el)
SI (2) SI3531133T1 (el)
TR (1) TR201903548T4 (el)
WO (1) WO2015181683A1 (el)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
CZ302070B6 (cs) 1998-04-21 2010-09-29 Micromet Ag Jednoretezcový multifunkcní polypeptid, polynukleotid, vektor obsahující tento polynukleotid, bunka transfekovaná tímto polynukleotidem, prostredek obsahující tento polypeptid, polynukleotid nebo vektor a jejich použití a zpusob identifikace aktiváto
EP1629012B1 (en) 2003-05-31 2018-11-28 Amgen Research (Munich) GmbH Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
CA2633594C (en) 2005-12-16 2021-10-26 Micromet Ag Means and methods for the treatment of tumorous diseases
US20090304657A1 (en) 2006-05-03 2009-12-10 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Chimeric t cell receptors and related materials and methods of use
KR101589759B1 (ko) 2007-04-03 2016-01-29 암젠 리서치 (뮌헨) 게엠베하 종간 특이적 ｃｄ３―입실론 결합 도메인
WO2008119566A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific bispecific binders
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
PL2344539T3 (pl) 2008-11-07 2015-07-31 Amgen Res Munich Gmbh Leczenie pediatrycznej ostrej białaczki limfoblastycznej
PL2982696T3 (pl) 2008-11-07 2019-08-30 Amgen Research (Munich) Gmbh Leczenie ostrej białaczki limfoblastycznej
KR101841781B1 (ko) 2009-10-27 2018-03-23 암젠 리서치 (뮌헨) 게엠베하 ＣＤ１９ｘＣＤ３ 이중특이적 항체를 투여하는 투약 용법
WO2012146394A1 (en) 2011-04-28 2012-11-01 Amgen Research (Munich) Gmbh Dosage regimen for administering a cd19xcd3 bispecific antibody to patients at risk for potential adverse effects
JO3529B1 (ar) 2013-02-08 2020-07-05 Amgen Res Munich Gmbh مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد

Also Published As

Publication number Publication date
US11079381B2 (en) 2021-08-03
PT3149480T (pt) 2019-03-21
EP3531133A1 (en) 2019-08-28
AU2015265578B2 (en) 2021-09-02
CA2948771C (en) 2023-10-17
LT3531133T (lt) 2023-11-10
HRP20231361T1 (hr) 2024-02-16
EP3149480A1 (en) 2017-04-05
PL3149480T3 (pl) 2019-06-28
HUE042407T2 (hu) 2019-06-28
WO2015181683A1 (en) 2015-12-03
SI3531133T1 (sl) 2023-12-29
FI3531133T3 (fi) 2023-11-02
CA2948771A1 (en) 2015-12-03
ES2715679T3 (es) 2019-06-05
AU2015265578A1 (en) 2016-11-17
PL3531133T3 (pl) 2024-01-29
EP4303585A3 (en) 2024-01-24
WO2015181683A4 (en) 2016-02-04
EP3531133B1 (en) 2023-08-23
HUE063648T2 (hu) 2024-01-28
PT3531133T (pt) 2023-11-07
DK3149480T3 (en) 2019-04-01
SI3149480T1 (sl) 2019-05-31
EP3149480B1 (en) 2018-12-26
ES2961565T3 (es) 2024-03-12
EP4303585A2 (en) 2024-01-10
RS64773B1 (sr) 2023-11-30
TR201903548T4 (tr) 2019-04-22
LT3149480T (lt) 2019-04-25
DK3531133T3 (da) 2023-11-06
US20170122947A1 (en) 2017-05-04

Similar Documents

Publication Publication Date Title
MX2023002251A (es) Antagonistas de union al eje pd-l1 y usos de los mismos para el tratamiento de cancer.
SG11202007686VA (en) Methods characterizing multiple analytes from individual cells or cell populations
MX2023000050A (es) Metodos de acondicionamiento de pacientes para tratamiento con linfocitos t.
PH12017502153A1 (en) Diagnostic methods for t cell therapy
CY1122973T1 (el) Συνθεση υγρου διαπιδυσης η οποια περιλαμβανει ουσιες αναστολης της κρυσταλλωσης
WO2016109782A3 (en) Methods and compositions for detecting colorectal neoplasias
MX2014005800A (es) Mutaciones del receptor notch humano y su uso.
TW201613637A (en) Methods of treating Alzheimer's Disease
MX2018004170A (es) Biomarcadores relacionados con enfermedades mediadas por interleucina-33 (il-33) y usos de los mismos.
MX2018001737A (es) Mecanismo de resistencia a inhibidores de bromodominio bet.
MX2018012143A (es) Métodos de diagnóstico para la toma de decisiones terapéuticas específicas del paciente en el cuidado del cáncer.
EP4279127A3 (en) Growth differentiation factor 15 as biomarker for metformin
CY1124768T1 (el) Μεθοδος για προβλεψη θεραπευτικης ωφελειας της anti-cd19 θεραπειας σε ασθενεις
EA202190474A1 (ru) Терапия на основе микро-рнк, направленная против lcp-1-позитивных раковых опухолей
CY1122474T1 (el) Μεθοδος διαγνωσης νευραλγιας του τριδυμου
MX2018007361A (es) Moléculas pequeñas para inhibir la actividad de quimiocinas, la actividad de una cinasa y/o el crecimiento de células cancerosas.
EA201491780A1 (ru) Мутанты c-raf, придающие резистентность к ингибиторам raf
CY1122600T1 (el) Στρωματοποιηση κινδυνου σε ασθενεις με οξεια λεμφοβλαστικη λευχαιμια εκ β προδρομων
Kim et al. ALK rearrangement in a pure squamous cell carcinoma: the challenge of detection of ALK rearrangement
MX2021009247A (es) Metodos, sistemas y kits para tratar enfermedades inflamatorias que se dirigen a il18r1.
EP4289970A3 (en) Circulating serum microrna biomarkers and methods for alzheimer's disease diagnosis
WO2015145388A3 (en) Methods of treating colorectal cancers harboring upstream wnt pathway mutations
EA201501095A1 (ru) Эффективное лечение нмрл и прогностический клинический маркер чувствительной к лечению опухоли
MX2018006250A (es) Biomarcador de enfermedad poliquistica renal y usos del mismo.
MX2018003313A (es) Celulas asesinas naturales modificadas con propiedades anti-fuctacticas y sus usos.